Market Overview:
The global cancer hormone therapy drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising awareness about cancer treatments, and technological advancements in the field of oncology. The global cancer hormone therapy drugs market is segmented on the basis of type into tamoxifen, aromatase inhibitors, antiandrogens, androgen synthesis inhibitors, and other types. The tamoxifen segment is expected to account for the largest share of the global market in 2018. This segment is also projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to its high usage rates for breast cancer treatment and its low cost compared with other types of hormonal therapies available in the market.
Product Definition:
Cancer hormone therapy drugs are a type of medication used to treat cancer. They work by blocking or slowing the growth of cancer cells.
Tamoxifen:
It is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer. It was first approved by the U.S. FDA in 1994 for post-menopausal women with breast cancer who had not undergone chemotherapy and radiation therapy. In Europe, it was approved for this indication in 1995 and 1996 respectively, while approval for its usage as hormone replacement therapy (HRT)in Japan came into effect from 1997 to 1998.
Aromatase Inhibitors:
Aromatase inhibitors are drugs that prevent the conversion of estrogen into oestrogen. They have a very specific mechanism of action, namely they target the aromatase enzyme which is responsible for converting testosterone to oestrogen. The most commonly used drug class are known as letrozole and anastrozole, both trade names for raloxifene.
Application Insights:
The breast cancer segment dominated the global cancer hormone therapy drugs market in 2017. This can be attributed to the increasing prevalence of breast and prostate cancers across the globe. Breast cancer is one of the most common types of tumor that occurs in women, affecting around 1 in 8 U.S citizens aged between 50 and 74 years old, along with about 2 million other women across America every year. It is also estimated that nearly 300,000 new cases will be diagnosed this year alone globally owing to high incidence rates coupled with a lack of awareness campaigns for early detection among both men and women regarding risk reduction measures such as regular checkups by healthcare professionals at an early stage when symptoms are minimal or non-existent.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased R&D investment by companies, and high adoption rate of novel drugs for treatment. Moreover, availability of reimbursement and increasing healthcare expenditure are also contributing toward growth in this region. According to a study published by The National Cancer Institute (NCI), in 2016 about 58% women with breast cancer and 64% prostate cancer patients received some form of hormonal therapy during their treatment journey as compared to 46% & 55%, respectively in 2011.
Growth Factors:
- Increasing incidence of cancer across the globe
- Growing awareness about cancer hormone therapy drugs among people
- Rising demand for better and more effective cancer treatments
- Technological advancements in the field of oncology that are helping to develop novel cancer hormone therapy drugs 5. Availability of government funding for research and development in the field of oncology
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Hormone Therapy Drugs Market Research Report
By Type
Tamoxifen, Aromatase Inhibitors, Antiandrogens, Androgen Synthesis Inhibitors, Other
By Application
Breast Cancer, Prostate Cancer
By Companies
Roche, Amgen, Pfizer, Teva, Takeda, Samyang Biopharmaceuticals, Tolmar, AstraZeneca, Novartis, Aspen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Hormone Therapy Drugs Market Report Segments:
The global Cancer Hormone Therapy Drugs market is segmented on the basis of:
Types
Tamoxifen, Aromatase Inhibitors, Antiandrogens, Androgen Synthesis Inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Prostate Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Amgen
- Pfizer
- Teva
- Takeda
- Samyang Biopharmaceuticals
- Tolmar
- AstraZeneca
- Novartis
- Aspen
Highlights of The Cancer Hormone Therapy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tamoxifen
- Aromatase Inhibitors
- Antiandrogens
- Androgen Synthesis Inhibitors
- Other
- By Application:
- Breast Cancer
- Prostate Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Hormone Therapy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer hormone therapy drugs are medications that help to treat cancer. These drugs can help to reduce the size of tumors, improve the quality of life for patients with cancer, and prolong their survival.
Some of the key players operating in the cancer hormone therapy drugs market are Roche, Amgen, Pfizer, Teva, Takeda, Samyang Biopharmaceuticals, Tolmar, AstraZeneca, Novartis, Aspen.
The cancer hormone therapy drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Hormone Therapy Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Hormone Therapy Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Hormone Therapy Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Hormone Therapy Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Hormone Therapy Drugs Market Size & Forecast, 2018-2028
4.5.1 Cancer Hormone Therapy Drugs Market Size and Y-o-Y Growth
4.5.2 Cancer Hormone Therapy Drugs Market Absolute $ Opportunity
Chapter 5 Global Cancer Hormone Therapy Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Hormone Therapy Drugs Market Size Forecast by Type
5.2.1 Tamoxifen
5.2.2 Aromatase Inhibitors
5.2.3 Antiandrogens
5.2.4 Androgen Synthesis Inhibitors
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Hormone Therapy Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Hormone Therapy Drugs Market Size Forecast by Applications
6.2.1 Breast Cancer
6.2.2 Prostate Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Hormone Therapy Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Hormone Therapy Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Hormone Therapy Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Hormone Therapy Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Hormone Therapy Drugs Market Size Forecast by Type
9.6.1 Tamoxifen
9.6.2 Aromatase Inhibitors
9.6.3 Antiandrogens
9.6.4 Androgen Synthesis Inhibitors
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Hormone Therapy Drugs Market Size Forecast by Applications
9.10.1 Breast Cancer
9.10.2 Prostate Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Hormone Therapy Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Hormone Therapy Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Hormone Therapy Drugs Market Size Forecast by Type
10.6.1 Tamoxifen
10.6.2 Aromatase Inhibitors
10.6.3 Antiandrogens
10.6.4 Androgen Synthesis Inhibitors
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Hormone Therapy Drugs Market Size Forecast by Applications
10.10.1 Breast Cancer
10.10.2 Prostate Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Hormone Therapy Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Hormone Therapy Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Hormone Therapy Drugs Market Size Forecast by Type
11.6.1 Tamoxifen
11.6.2 Aromatase Inhibitors
11.6.3 Antiandrogens
11.6.4 Androgen Synthesis Inhibitors
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Hormone Therapy Drugs Market Size Forecast by Applications
11.10.1 Breast Cancer
11.10.2 Prostate Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Hormone Therapy Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Hormone Therapy Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Hormone Therapy Drugs Market Size Forecast by Type
12.6.1 Tamoxifen
12.6.2 Aromatase Inhibitors
12.6.3 Antiandrogens
12.6.4 Androgen Synthesis Inhibitors
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Hormone Therapy Drugs Market Size Forecast by Applications
12.10.1 Breast Cancer
12.10.2 Prostate Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Hormone Therapy Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Hormone Therapy Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Hormone Therapy Drugs Market Size Forecast by Type
13.6.1 Tamoxifen
13.6.2 Aromatase Inhibitors
13.6.3 Antiandrogens
13.6.4 Androgen Synthesis Inhibitors
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Hormone Therapy Drugs Market Size Forecast by Applications
13.10.1 Breast Cancer
13.10.2 Prostate Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Hormone Therapy Drugs Market: Competitive Dashboard
14.2 Global Cancer Hormone Therapy Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Amgen
14.3.3 Pfizer
14.3.4 Teva
14.3.5 Takeda
14.3.6 Samyang Biopharmaceuticals
14.3.7 Tolmar
14.3.8 AstraZeneca
14.3.9 Novartis
14.3.10 Aspen
